Prolight Diagnostics advanced its Psyros POC platform, secured key patents, and reported a net loss of SEK 10.9 million in Q1 2025, with no sales and increased development costs. The company is preparing for pivotal clinical studies and a rights issue to fund commercialization.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.